• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Respir Investig . SARS-CoV-2 co-detection with other respiratory pathogens-descriptive epidemiological study

tetano

Editor, Senior Moderator
Respir Investig


. 2024 Aug 3;62(5):884-888.
doi: 10.1016/j.resinv.2024.07.016. Online ahead of print. SARS-CoV-2 co-detection with other respiratory pathogens-descriptive epidemiological study

Ken Arimura[SUP] 1 [/SUP], Ken Kikuchi[SUP] 2 [/SUP], Yasuto Sato[SUP] 3 [/SUP], Hitomi Miura[SUP] 4 [/SUP], Asako Sato[SUP] 5 [/SUP], Hideki Katsura[SUP] 6 [/SUP], Mitsuko Kondo[SUP] 6 [/SUP], Michio Itabashi[SUP] 7 [/SUP], Etsuko Tagaya[SUP] 6 [/SUP]



Affiliations
Abstract

Background: Co-detection of respiratory pathogens with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is poorly understood. This descriptive epidemiological study aimed to determine the effect of the interaction of different respiratory pathogens on clinical variables.
Methods: We retrospectively reviewed the results of comprehensive multiplex polymerase chain reaction (PCR) testing from November 2020 to March 2023 to estimate respiratory pathogen co-detection rates in Shinjuku, Tokyo. We evaluated the interactions of respiratory pathogens, particularly SARS-CoV-2, between observed and expected co-detection. We estimated the trend of co-detection with SARS-CoV-2 in terms of age and sex and applied a multiple logistic regression model adjusted for age, testing period, and sex to identify influencing factors between co-detection and single detection for each pathogen.
Results: Among 57,746 patients who underwent multiplex PCR testing, 10,516 (18.2%) had positive for at least one of the 22 pathogens. Additionally, 881 (1.5%) patients were confirmed to have a co-detection. SARS-CoV-2 exhibited negative interactions with adenovirus, coronavirus, human metapneumovirus, parainfluenza virus, respiratory syncytial virus, and rhino/enterovirus. SARS-CoV-2 co-detection with other pathogens occurred most frequently in patients of the youngest age group (0-4 years). A multiple logistic regression model indicated that younger age was the most influential factor for SARS-CoV-2 co-detection with other respiratory pathogens.
Conclusion: The study highlights the prevalence of SARS-CoV-2 co-detection with other respiratory pathogens in younger age groups, necessitating further exploration of the clinical implications and severity of SARS-CoV-2 co-detection.

Keywords: FILMARRAY®; Multiplex PCR testing; SARS-CoV-2 co-detection; respiratory pathogens.

 
Back
Top Bottom